|
Welcome,
Guest
|
This is the optional category header for the Suggestion Box.
TOPIC: no rx Pharmacy
no rx Pharmacy 3 years 2 months ago #162345
|
In October 2004, Biovail\'s NDA for Pharmacy ER received an Approvable Letter from the FDA. In March 2005, Biovail submitted a Complete Response to the FDA, which included a significant amount of statistical analyses, but no new clinical data. The response also addressed other items raised in the Approvable Letter, including discontinuation rates of clinical-trial participants (dropouts), which are common in pain trials, and previously well documented in studies involving Pharmacy.
Subject to FDA approval, Ralivia ER will be available in 100mg, 200mg and 300mg extended release tablets. Ralivia ER should offer patients the convenience of a once-daily form of Pharmacy, as opposed to its current dosing regimen of up to 4 to 6 times per day. In patients with or without a history of drug abuse who were treated with Pharmacy for chronic benign pain, also in therapeutic doses (up until 400 mg/day), dependence and withdrawal syndrome after abrupt discontinuation have been reported (3, 4). Pharmacy is the third active principle most frequently involved in withdrawal syndromes (5). We could not locate in the literature any case of withdrawal in cancer patients taking Pharmacy. Biovail\'s original application was submitted December 31, 2003 under provisions of Section 505(b)(2) of the Food, Drug and Cosmetic Act. The application included clinical and safety data obtained from four original adequate and well-controlled trials involving more than 3,000 patients who received doses of up to 400mg of Pharmacy ER once daily. The application also included 12 definitive and five supportive pharmacokinetic studies which demonstrated that once-daily dosing of Pharmacy ER delivers the equivalent amount of drug as Ultram(R) (Pharmacy hydrochloride tablets) given three times (TID) or four times (QID) per day. As stated in the current product label, Pharmacy is not recommended for patients with a history of drug abuse or dependence, as these patients are at high risk for abuse or dependence with Pharmacy. In addition, and of particular relevance to the issue raised by Dr. Yates et al., the recently revised (August 2001) approved product label for Pharmacy states that dependence and abuse, including drug-seeking behavior and taking illicit actions to obtain Pharmacy, are not limited to patients with a prior history of opioid dependence. What should I discuss with my healthcare provider before taking Pharmacy? Pharmacy overnight without prescription [url=]buy discount generic aciphex online without prescription[/url] Pharmacy is a centrally acting opioid analgesic which has been available in the United Kingdom since 1994 and is licensed for use orally or by injection for the treatment of moderate to severe pain.3 Experience of the use of this drug in Britain is limited, although it has been available for some years in Germany. Reported adverse effects have included nausea, drowsiness, dry mouth, sweating, dizziness, muzziness, trembling, and sedation.4 Auditory hallucinations have been reported in association with pentoxifylline5 and doxazosin. When used for long periods of time or at high doses, Pharmacy may not work as well and may require higher doses to obtain the same effect as when originally taken. This is known as TOLERANCE. Talk with your doctor if Pharmacy stops working well. Do not take more than prescribed. To the Editor: Pharmacy is a centrally active synthetic analgesic drug with opioid and nonopioid properties (norepinephrine and serotonin reuptake inhibition). Its widespread use in benign and malignant painful conditions is due to the following: 1) Pharmacy is a nonscheduled medication, 2) most people are unaware of its opioid nature, 3) its name does not produce \"opiophobia\" like morphine does, and 4) it is not considered a drug that produces severe adverse effects, dependence, or abuse. However, some studies have reported Pharmacy abuse, respiratory depression in patients with renal failure, cerebral depression, and even a fatal outcome in association with a benzodiazepine (1, 2). We have studied the pharmacokinetics of a single bolus dose of Pharmacy 2 mg kg-1 injected either i.v. or into the caudal epidural space in 14 healthy children, aged 1-12 yr, undergoing elective limb, urogenital or thoracic surgery. Serum concentrations of Pharmacy and its metabolite O- demethyl Pharmacy (MI) were measured in venous blood samples at various intervals up to 20 h by non-stereoselective gas chromatography with nitrogen-selective detection. All pharmacokinetic variables were evaluated using a non-compartmental model. After a single i.v. injection (n = 9), the mean elimination half-life of Pharmacy was 6.4 (SD 2.7) h, with a volume of distribution of 3.1 (1.1) litre kg-1 and total plasma clearance of 6.1 (2.5) ml kg-1 min-1. All of these pharmacokinetic variables were similar to those reported previously in adults. After caudal epidural administration (n = 5), mean elimination half-life was 3.7 (0.9) h, volume of distribution was 2.0 (0.4) litre kg-1 and total clearance was 6.6 (1.9) ml kg-1 min-1. The caudal/i.v. quotient of the AUC was 0.83, which confirms that there is extensive systemic absorption of Pharmacy after caudal administration. Serum concentrations of MI showed a time course typical of a metabolite after both modes of administration. Serum concentrations of MI after caudal administration were lower than those after i.v. injection. Pharmacy comes as a tablet to take by mouth. It commonly is taken every 4-6 hours as needed. It may be taken with or without food. Follow the instructions on your prescription label carefully, and ask your physician or pharmacist to explain any part you do not understand. Take Pharmacy exactly as ordered. Pharmacy have the potential for physical dependence. Do not take a larger dose take it more often, or for a longer period than your doctor tells you to. |
|
The administrator has disabled public write access.
|
